One Case of Exfoliative Dermatitis Induced by Norvancomycin Hydrochloride for Injection Combined with Imipenem and Cilastatin Sodium for Injection

Abstract

CLC Number:

R994.11

CHEN Furong, CHEN Yanli, DAI Jinzhi, DENG Lili, HU Junfei. One Case of Exfoliative Dermatitis Induced by Norvancomycin Hydrochloride for Injection Combined with Imipenem and Cilastatin Sodium for Injection[J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 623-624.

References

[1] 刘丽英, 李勇, 古淑仪. 万古霉素致白细胞减少症38例回顾性分析[J]. 中国药物警戒, 2012, 9(2):117-118.
[2] 杨淑桂, 郭冬杰, 周星. 注射用盐酸万古霉素致红人综合征1例[J]. 中国药物警戒, 2011, 8(10):636.
[3] Min Z, Garcia R R, Murillo M, et al.Vancomycin-associated Henoch-Sch nlein purpura[J]. Journal of Infection and Chemoth-erapy, 2017, 23(3): 180-184.
[4] Minhas J S, Wickner P G, Long A A, et al.Immune-mediated reactions to vancomycin: a systematic case review and analysis[J]. Annals of Allergy, Asthma & Immunology, 2016, 116(6): 544-553.
[5] Benoit L, Gray M H, Sligl W I.Severe tremor due to vancomycin therapy: a case report and literature review[J]. International Journal of Infectious Diseases, 2012, 16(8): e636-e637.
[6] 毛璐, 李锦. 去甲万古霉素与万古霉素不良反应分析[J]. 中国医药, 2014, 9(1): 121-123.
[7] 刘杨, 吴菊芳, 萧正伦, 等. 1031例患者应用去甲万古霉素不良反应观察[J]. 中华内科杂志, 2004, 43(11): 815-819.
[8] 张艳, 张运周, 宿英英. 去甲万古霉素致粒细胞缺乏症及红人综合征[J]. 药物不良反应杂志, 2010, 12(4): 290-292.
[9] 李琦恒, 倪鸿昌. 亚胺培南/西司他丁不良反应回顾性调查分析[J]. 中国药物应用与监测, 2010, 7(4):223-225.
[10] 张祥霞, 任丽佳. 注射用亚胺培南西司他丁钠致过敏性休克1例[J]. 中国药物警戒, 2014, 11(1):60.
[11] 徐锦龙, 王雄雄, 陈武, 等. 亚胺培南西司他丁钠致中毒性表皮坏死松解型药疹1例[J]. 中国药物应用与监测, 2014, (5):325-326.
[12] Atanaskovi -Markovi M, Gaeta F, Gavrovi -Jankulovi M, et al.Tolerability of imipenem in children with IgE-mediated hypersensitivity to penicillins[J]. Journal of Allergy and Clinical Immunology, 2009, 124(1): 167-169.
[13] 刘桦, 张佳丽. 药物过敏反应的免疫学机制研究进展[J]. 中国现代应用药学, 2006, 23(4): 284-286,297.

[1]	SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
[2]	ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
[3]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[4]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[5]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[6]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[7]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[8]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[9]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[10]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[11]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[12]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[13]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[14]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[15]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.